Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
The American Journal of Gastroenterology|July 18, 2023
P008 A Novel Smartphone Application to Reduce Infusion Suite Wait TimesJoan Chandra, Matthew Siegel, Odalie Bernash, et al.Journal of Crohn'S & Colitis|November 30, 2018
Integrated Care for Crohn's Disease: A Plea for the Development of Clinical Decision Support SystemsNathalie Y Pauwen, Edouard Louis, Corey Siegel, et al.Rhode Island Medical Journal (2013)|October 27, 2022
Treat-to-Target: The Era of Targeted Immunosuppressive Agents in IBD ManagementDaniel Marino, Siddharth Singh, Jason Hou, et al.Inflammatory Bowel Diseases|September 3, 2011
Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohortLori A Ashworth, Amy Billett, Paul Mitchell, et al.The American Journal of Gastroenterology|June 6, 2012
IBS patients' willingness to take risks with medicationsBrian E Lacy, Kelly K Everhart, Kirsten T Weiser, et al.Journal of Crohn'S & Colitis|July 12, 2025
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpointJean-Frederic Colombel, Jianmin Wu, Taku Kobayashi, et al.BMJ Open|April 2, 2022
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)Konstantinos Papamichael, Vipul Jairath, Guangyong Zou, et al.Journal of Crohn'S & Colitis|October 21, 2023
Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBDSophie Vieujean, James O Lindsay, Ferdinando D'Amico, et al.The American Journal of Gastroenterology|November 4, 2010
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Geert R D'Haens, Remo Panaccione, Peter D R Higgins, et al.Pageof 1